RU2019106483A - Местная терапия рапамицином - Google Patents
Местная терапия рапамицином Download PDFInfo
- Publication number
- RU2019106483A RU2019106483A RU2019106483A RU2019106483A RU2019106483A RU 2019106483 A RU2019106483 A RU 2019106483A RU 2019106483 A RU2019106483 A RU 2019106483A RU 2019106483 A RU2019106483 A RU 2019106483A RU 2019106483 A RU2019106483 A RU 2019106483A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- composition according
- paragraphs
- glycol
- treatment
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 29
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 12
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 6
- 239000007788 liquid Substances 0.000 claims 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 4
- 229960002930 sirolimus Drugs 0.000 claims 4
- 208000003120 Angiofibroma Diseases 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 206010040882 skin lesion Diseases 0.000 claims 3
- 231100000444 skin lesion Toxicity 0.000 claims 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000002033 PVDF binder Substances 0.000 claims 2
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 2
- 208000009443 Vascular Malformations Diseases 0.000 claims 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 2
- 235000011187 glycerol Nutrition 0.000 claims 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- 208000032541 Epidermal naevus Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 206010025219 Lymphangioma Diseases 0.000 claims 1
- 206010027145 Melanocytic naevus Diseases 0.000 claims 1
- 201000002571 Melkersson-Rosenthal syndrome Diseases 0.000 claims 1
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims 1
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 claims 1
- 208000007256 Nevus Diseases 0.000 claims 1
- 208000007531 Proteus syndrome Diseases 0.000 claims 1
- 206010037649 Pyogenic granuloma Diseases 0.000 claims 1
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 1
- 229940073669 ceteareth 20 Drugs 0.000 claims 1
- 229940081733 cetearyl alcohol Drugs 0.000 claims 1
- 208000010575 cherry hemangioma Diseases 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 201000011560 gingival overgrowth Diseases 0.000 claims 1
- 229940075507 glyceryl monostearate Drugs 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 1
- 235000019271 petrolatum Nutrition 0.000 claims 1
- 235000020043 port wine Nutrition 0.000 claims 1
- 229960004063 propylene glycol Drugs 0.000 claims 1
- 239000008213 purified water Substances 0.000 claims 1
- 210000001732 sebaceous gland Anatomy 0.000 claims 1
- 201000005574 senile angioma Diseases 0.000 claims 1
- 229940083037 simethicone Drugs 0.000 claims 1
- 235000010199 sorbic acid Nutrition 0.000 claims 1
- 239000004334 sorbic acid Substances 0.000 claims 1
- 229940075582 sorbic acid Drugs 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000003871 white petrolatum Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662372940P | 2016-08-10 | 2016-08-10 | |
| US62/372,940 | 2016-08-10 | ||
| PCT/US2017/046320 WO2018031789A1 (en) | 2016-08-10 | 2017-08-10 | Topical rapamycin therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019106483A true RU2019106483A (ru) | 2020-09-11 |
| RU2019106483A3 RU2019106483A3 (enExample) | 2020-12-04 |
Family
ID=59684091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019106483A RU2019106483A (ru) | 2016-08-10 | 2017-08-10 | Местная терапия рапамицином |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190167649A1 (enExample) |
| EP (1) | EP3496712A1 (enExample) |
| JP (1) | JP2019527711A (enExample) |
| KR (1) | KR20190039220A (enExample) |
| CN (1) | CN109689053A (enExample) |
| AU (1) | AU2017311491A1 (enExample) |
| BR (1) | BR112019002689A2 (enExample) |
| CA (1) | CA3032473A1 (enExample) |
| MX (1) | MX2019001670A (enExample) |
| RU (1) | RU2019106483A (enExample) |
| WO (1) | WO2018031789A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL302385B2 (en) | 2017-01-06 | 2024-06-01 | Palvella Therapeutics Inc | Non-aqueous preparations of mTOR inhibitors and methods of use |
| WO2019156999A1 (en) * | 2018-02-06 | 2019-08-15 | Georgetown University | TOPICAL mTOR INHIBITORS FOR CUTANEOUS PROLIFERATIVE AND VASCULAR CONDITIONS |
| JP2021530463A (ja) | 2018-07-02 | 2021-11-11 | パルヴェラ セラピューティクス、インク． | ｍＴＯＲ阻害剤の無水組成物および使用方法 |
| EP3829578A4 (en) * | 2018-08-30 | 2022-08-17 | Chemistryrx | COMPOSITIONS CONTAINING SIROLIMUS |
| CN109431997B (zh) * | 2018-12-20 | 2021-06-04 | 武汉科福新药有限责任公司 | 一种雷帕霉素局部注射制剂及其制备方法 |
| JP2022521006A (ja) | 2019-02-20 | 2022-04-04 | エイアイ・セラピューティクス・インコーポレーテッド | 局所ラパマイシン製剤ならびに顔面血管線維腫および他の皮膚疾患の治療におけるそれらの使用 |
| WO2020175131A1 (ja) * | 2019-02-27 | 2020-09-03 | 国立大学法人大阪大学 | 脈管異常治療用外用剤 |
| JP7755854B2 (ja) * | 2020-01-24 | 2025-10-17 | ノーベルファーマ株式会社 | ラパマイシン含有外用剤 |
| AU2020277132B1 (en) * | 2020-11-24 | 2021-11-04 | Aft Pharmaceuticals Limited | A Rapamycin Composition |
| AU2023203871B1 (en) * | 2023-06-20 | 2024-07-25 | Aft Pharmaceuticals Ltd | A Rapamycin Method of Treatment and Composition |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9606452D0 (en) | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
| EP0937082A2 (en) | 1996-07-12 | 1999-08-25 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| GB9723669D0 (en) | 1997-11-07 | 1998-01-07 | Univ Aberdeen | Skin penetration enhancing components |
| AU2003259803B2 (en) | 2002-08-12 | 2007-08-02 | The Regents Of The University Of Michigan | Diagnosis and treatment of tuberous sclerosis |
| EP1853612A1 (en) | 2005-03-02 | 2007-11-14 | Wyeth | Purification of rapamycin |
| AU2007211613C1 (en) | 2006-02-02 | 2018-01-04 | Novartis Ag | Tuberous Sclerosis treatment |
| US20120022095A1 (en) | 2010-06-24 | 2012-01-26 | Teng Joyce M C | Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis |
| WO2012142145A1 (en) * | 2011-04-12 | 2012-10-18 | Dow Pharmaceutical Sciences | Methods of treating skin conditions exhibiting telangiectasia |
| CA2899206C (en) * | 2013-01-24 | 2019-07-09 | Transderm, Inc. | Compositions for transdermal delivery of mtor inhibitors |
| HUP1400075A2 (hu) * | 2014-02-14 | 2015-08-28 | Druggability Technologies Ip Holdco Jersey Ltd | Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói |
| KR20180081501A (ko) * | 2015-09-24 | 2018-07-16 | 드렉셀유니버시티 | 진피 장애를 치료하거나 예방하는 신규한 조성물 및 방법 |
| CN105663027B (zh) * | 2016-04-01 | 2018-12-18 | 中国人民解放军广州军区武汉总医院 | 西罗莫司外用制剂、其制备方法及用途 |
-
2017
- 2017-08-10 CA CA3032473A patent/CA3032473A1/en not_active Abandoned
- 2017-08-10 US US16/324,274 patent/US20190167649A1/en not_active Abandoned
- 2017-08-10 EP EP17755383.1A patent/EP3496712A1/en not_active Withdrawn
- 2017-08-10 WO PCT/US2017/046320 patent/WO2018031789A1/en not_active Ceased
- 2017-08-10 AU AU2017311491A patent/AU2017311491A1/en not_active Abandoned
- 2017-08-10 CN CN201780049324.6A patent/CN109689053A/zh active Pending
- 2017-08-10 KR KR1020197006896A patent/KR20190039220A/ko not_active Ceased
- 2017-08-10 JP JP2019506721A patent/JP2019527711A/ja active Pending
- 2017-08-10 RU RU2019106483A patent/RU2019106483A/ru unknown
- 2017-08-10 BR BR112019002689A patent/BR112019002689A2/pt not_active IP Right Cessation
- 2017-08-10 MX MX2019001670A patent/MX2019001670A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018031789A1 (en) | 2018-02-15 |
| US20190167649A1 (en) | 2019-06-06 |
| JP2019527711A (ja) | 2019-10-03 |
| CA3032473A1 (en) | 2018-02-15 |
| MX2019001670A (es) | 2019-07-04 |
| CN109689053A (zh) | 2019-04-26 |
| BR112019002689A2 (pt) | 2019-05-14 |
| EP3496712A1 (en) | 2019-06-19 |
| RU2019106483A3 (enExample) | 2020-12-04 |
| AU2017311491A1 (en) | 2019-02-07 |
| KR20190039220A (ko) | 2019-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019106483A (ru) | Местная терапия рапамицином | |
| JP2019527711A5 (enExample) | ||
| JP5953608B2 (ja) | バイオフィルム抑制剤 | |
| HRP20191523T1 (hr) | Paraziticidne kombinacije spirocikličkog izoksazolina | |
| JP2011037904A5 (enExample) | ||
| RU2015137146A (ru) | Композиции для личной гигиены | |
| RU2018144755A (ru) | Соединения для стимуляции роста волос и/или ингибирования или замедления выпадения волос у человека и композиции для их применения | |
| WO2017219835A1 (zh) | 抗菌消炎漱口水 | |
| WO2011028057A3 (en) | Novel bacteriophage and antibacterial composition comprising the same | |
| CN102573769A (zh) | 洁齿剂组合物 | |
| JP2018052916A (ja) | 外用組成物 | |
| JP2018062519A (ja) | 眼科用組成物 | |
| CN103974617B (zh) | 百里酚和桃拓酚抗菌组合物 | |
| JP5614020B2 (ja) | 歯磨組成物 | |
| JP2015521599A5 (enExample) | ||
| RU2009135763A (ru) | Способ консервирования | |
| JP2013527126A5 (enExample) | ||
| JP4248172B2 (ja) | ソフトコンタクトレンズケア用品 | |
| CN102688257A (zh) | 一种液态分子碘消毒制剂、制备方法及使用的容器 | |
| WO2017219579A1 (zh) | 长效抑菌型漱口水 | |
| JP6150271B2 (ja) | 口腔内好気性細菌用静菌剤 | |
| CN106176442A (zh) | 一种保护皮肤的清洁布 | |
| RU2015153704A (ru) | Антиперспирантная композиция | |
| JP5064114B2 (ja) | 眼科用組成物 | |
| JP2006312613A (ja) | 口腔用組成物 |